Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors
This is a dose escalation and expansion study of CS1003. This trial is recruiting patients with: soft-tissue sarcoma, malignant pleural mesothelioma, bladder cancer, Merkel-cell carcinoma, gastro-intestinal stromal tumour (GIST), gastric cancers, oesophageal carcinoma, small cell lung cancer, large cell lung cancer, head and neck squamous cell carcinoma or cutaneous cell carcinoma, or any solid tumours with MSI-H or dMMR.
Border Medical Oncology Research Unit is only participating in (expansion) Phase 1B of the study.